This is a Phase 2b, randomized, double blind, placebo and active controlled study with an Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing bunionectomy.
Near the completion of surgery, a single dose of study drug (CPL-01, saline placebo, or ropivacaine HCl) will be infiltrated. Subjects will remain in the hospital/research facility for a minimum of 72 hours after the start of study drug administration to undergo postoperative assessments. Subjects will return to the study site on Day 7 to complete follow up assessments, on Day 28 for follow-up assessments including an X-Ray, and on Day 42 for the end-of-study (EOS) visit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
73
Injection of protocol-specified volume of local analgesic
Arizona Research Center
Phoenix, Arizona, United States
Trovare Clinical Research
Bakersfield, California, United States
Jean Brown Research
Salt Lake City, Utah, United States
AUC72
Pain score through 72 hours post-operative
Time frame: 72 hours post-operative
Opioid use (MME)
Opioid use through 72 hours post-operative
Time frame: 72 hours post-operative
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.